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Abstract
Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the
gastrointestinal tract associated with multifactorial conditions such as ulcerative
colitis and Crohn’s disease. Although the underlying mechanisms of IBD remain
unclear, growing evidence has shown that dysregulated immune system
reactions in genetically susceptible individuals contribute to mucosal
inflammation. However, conventional treatments have been effective in inducing
remission of IBD but not in preventing the relapse of them. In this way,
mesenchymal stromal cells (MSC) therapy has been recognized as a promising
treatment for IBD due to their immunomodulatory properties, ability to
differentiate into several tissues, and homing to inflammatory sites. Even so,
literature is conflicted regarding the location and persistence of MSC in the body
after transplantation. For this reason, recent studies have focused on the
paracrine effect of the biofactors secreted by MSC, especially in relation to the
immunomodulatory potential of soluble factors (cytokines, chemokines, and
growth factors) and extracellular vehicles that are involved in cell communication
and in the transfer of cellular material, such as proteins, lipids, and nucleic acids.
Moreover, treatment with interferon-γ, tumor necrosis factor-α, and interleukin-
1β causes MSC to express immunomodulatory molecules that mediate the
suppression via cell-contact dependent mechanisms. Taken together, we present
an overview of the role of bioactive factors and cell membrane proteins derived
from MSC as a cell-free therapy that can improve IBD treatment.
Key words: Bioactive factors; Cell membrane; Mesenchymal stem cells; Cell-free therapy;
Inflammatory bowel diseases
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Core tip: Recent experimental studies have suggested that both bioactive factors and
surface proteins of mesenchymal stem cells demonstrate great therapeutic potential for
overcoming the deficiencies of current therapies for inflammatory bowel diseases. Our
goal in this review is to describe cell-free therapy based upon the therapeutic potential of
mesenchymal stem cells, while avoiding the practical issues associated with the use of
living cells.
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INTRODUCTION
Inflammatory bowel diseases (IBD) comprise ulcerative colitis  (UC) and Crohn’s
disease (CD), both of which are chronically multifactorial inflammatory disorders of
the  gastrointestinal  system.  Although the  pathogenesis  of  IBD remains  unclear,
mounting  evidence  suggests  that  abnormal  immune  regulation  in  genetically
susceptible  individuals  and/or  environmental  factors  contribute  to  mucosal
inflammation[1-3]. Conventional treatments for IBD involve immunosuppressive drugs
that lead to the remission of intestinal inflammation and related symptoms. However,
there is no known medical/surgical cure for IBD[4,5]. Therefore, additional therapeutic
strategies, such as cell-based therapy, are required for unresponsive patients.
In this way, mesenchymal stromal cells (MSC) are a promising strategy for treating
inflammatory  diseases,  immune disorders,  and tissue  regeneration  due  to  their
immunomodulatory  properties,  ability  to  differentiate  into  several  tissues,  and
homing to inflammatory sites,  by which they control  inflammation and the pro-
duction of cytokines[6-8]. However, there are conflicts in the literature regarding the
location and persistence of  MSC in the body after  transplantation.  Cell-tracking
studies  have  shown that  most  MSC are  localized in  the  lungs  after  intravenous
infusion and have a short-term survival span[9-12]. After 24 h of infusion, MSC tend to
disappear from the lungs, suggesting that they probably transmit their effects to
resident cells[9].  Based on this,  MSC may interact  with resident cells  through the
secretion of paracrine factors or cell-cell communication[13-15].
Recent studies have focused on the paracrine effect of the biofactors secreted by
MSC, especially in relation to the immunomodulatory potential of soluble factors
(cytokines,  chemokines,  and growth factors)[16-18].  Also,  MSC alter  their  immune
function in response to the inflammatory environment, especially by the stimulation
of proinflammatory cytokines interferon-γ (IFN-γ) and the tumor necrosis factor
(TNF)-α[19,20]. After activation, MSC upregulate the expression of interleukin (IL)-6, IL-
10,  indoleamine  2,3  dioxygenase  (IDO),  transforming  growth  factor  (TGF),
prostaglandin E2 (PGE-2), hepatocyte growth factor (HGF), nitric oxide, and heme
oxygenase-1[20-23].  It  is also known that MSC are capable of releasing extracellular
vehicles (EVs) that are involved both in cell communication and in the transfer of
cellular material,  such as proteins,  lipids,  and nucleic  acids[24-26].  Moreover,  MSC
express  immunomodulatory molecules  in  their  cell  membrane such as  ATPases,
CD73, and Toll-like receptors (TLRs)[27-29], and, under inflammatory conditions, they
express the programmed death ligand 1 (PD-L1) and the Fas ligand[22,30-34]. For this
reason, both biofactors secretion and cell contact may be required for efficient MSC
immunomodulation[14,35].
Therefore, the study of bioactive factors and cell  membrane molecules of MSC
becomes important in the search for new cell-free therapeutic methodologies that aim
to reduce the complications associated with the administration of MSC but while
preserving the immunological properties of these cells.
IBD
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IBD are chronic inflammatory disorders of the gastrointestinal system associated with
multifactorial conditions, such as UC and CD. Although the underlying mechanisms
of UC and CD remain uncertain, growing evidence has shown that failure of the
epithelial barrier and dysregulation of the immune system in genetically predisposed
individuals contribute to mucosal inflammation[1-3]. These diseases are characterized
by the dysfunction of mucosal T cells, alteration in the production and secretion of
cytokines, and cellular inflammation affecting the digestive tract, especially the distal
small intestine and colon mucosa[36]. While CD may affect any part of the gastroin-
testinal  segment  and  is  characterized  by  an  inflammatory  process  that  recruits
macrophages and forms granulomas, UC is generally limited to the colon and rectum,
characterized  by  neutrocytic  infiltrate  with  formation  of  cryptic  abscesses  and
epithelial  ulceration[37].  Patients  with  UC  experience  continuous  inflammation
confined to the mucosal layer. In CD, the inflammation is discontinuous and affects all
intestine layers[2].
At the clinic, patients with IBD have recurrent episodes of abdominal pain, dia-
rrhea, bloody stools, and weight loss. Moreover, they may present extra intestinal
manifestations in the skin, joints, eyes, and less frequently in the abdominal organs,
for example, the biliary tract[38]. Treatment of IBD is based on the severity, site, clinical
manifestations, and complications of the disease in each case. Several cellular and
molecular pathological pathways have been identified as targets for IBD treatment[39].
The exacerbated progression of IBD requires a scale ranging from anti-inflammatory
treatment to biological agents, usually with limited success[40]. Furthermore, medical
treatments  are  expensive  and common drugs  are  toxic  and ineffective  for  most
patients, making surgical resection of the parts of the intestine necessary in many
cases[2,41].  Regarding the  progress  achieved by  intensive  clinical-drug treatment,
approximately 20% of patients with UC and 50% of patients with CD require surgical
intervention  within  10  years  of  diagnosis[41].  Accordingly,  some  studies  have
addressed MSC therapy as a promising approach for treating IBD[42].
MSC
MSC are multipotent cells  capable of  differentiating into mesodermal lines,  par-
ticularly osteoblastic, adipogenic, and chondrogenic strains[43,44]. There is controversy
over  the  naming  and  definition  of  MSC  in  the  scientific  community.  The  term
“mesenchymal stromal cell” is used in parallel with the terms “mesenchymal stem
cell” and “multipotent mesenchymal stromal cell”[45]. MSC are indeed a heterogeneous
population of cells characterized immunophenotypically by the expression of CD73,
CD90, and CD105 and do not present the expression of CD45, CD34, CD11, CD14,
CD19,  CD79A,  and  human  leukocyte  antigen  (HLA)-DR  hematopoietic  lineage
markers[46].  Most  of  the  knowledge  about  these  cells  was  generated  from  bone
marrow-derived MSC. However, the origin of MSC production has been expanded to
other  tissues,  including  muscle,  adipose,  and  neonatal  tissues[47,48].  Recently,
Soontararak et al[49] demonstrated that MSC derived from induced pluripotent stem
cells are equivalent to MSC derived from adipose tissue in terms of improving the
intestinal healing in IBD model.
MSC exhibit great therapeutic potential in regenerative medicine owing to their
ability to differentiate in vitro, homing (the process in which cells are able to migrate
and graft to the tissues) to inflamed tissues after in vivo infusion, and the secretion of
various bioactive molecules[8]. In addition, the immunomodulatory properties of MSC
suggest that even MSC of the incompatible HLA may be suitable for a wide variety of
new therapeutic applications, especially for cellular therapy of inflammatory and
autoimmune diseases[50]. Traditionally, MSC are isolated from bone marrow, but other
cellular sources may be of greater benefit due to the higher number of MSC or easier
accessibility[13]. Moreover, MSC from different tissue sources share several phenotypic
and functional features. Even so, there are subtle peculiarities in the expression and
differentiation abilities of specific markers on cell surface[13,45].
Studies  have  compared the  ability  of  MSC from different  tissues  to  suppress
peripheral blood cells, and adipose tissue-derived MSC have demonstrated a greater
immunomodulatory effect than MSC from other sources[51,52]. Although adipose and
bone marrow-derived MSC share  several  properties,  there  are  variation in  gene
expression and growth factor  secretion profiles[53].  In  addition,  various  types  of
adipose  tissue  may have  distinct  properties.  MSC isolated from abdominal  and
mammary adipose tissue,  for  example,  present  discrepancy in the expression of
fibroblast growth factor and receptor, suggesting variability in angiogenic potential[54].
Neonatal tissues (cord blood, umbilical cord, placenta, amnion, and chorion) have
been  an  alternative  for  MSC isolation.  These  tissues  are  usually  discarded  as  a
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residual product after delivery and can be obtained in large quantities in an easy and
noninvasive  way[55].  Another  relevant  advantage of  neonatal  tissues  is  that  they
supply immature cells, which present a lower risk of mutations and superior cell
activity, such as increased differentiation, homing, and grafting ability[56,57]. Previous
studies  have  shown  that  neonatal  sources  exhibit  superior  proliferation  and
immunosuppressive and regenerative potential when compared to adult tissues, for
example, bone marrow and adipose tissue[47,58].
Immunological properties of MSC
MSC have demonstrated low levels of HLA or major histocompatibility complex
(MHC) class I and insignificant levels of HLA class II. Moreover, they do not express
co-stimulatory molecules such as CD40, CD40L, B7-1 (CD80), and B7-2 (CD86)[22,51,59-61].
Consequently,  MSC present low immunogenicity and may “escape” the immune
system due to their surface phenotypes that are not recognized by T cells. Absence of
MHC II or T cell co-stimulatory molecules make the MSC immune-privileged cells
and may explain the mechanism by which MSC are not  recognized by T cells[62].
Interestingly,  both  syngeneic  and  allogeneic  MSC  are  immunotolerable  by  the
receptor[63].
MSC have presented a high immunosuppressive capacity and interaction with
immune cells through several mechanisms. Studies have shown that MSC-mediated
immunosuppression may occur  through the secretion of  soluble  factors  and the
presence of MSC membrane protein[51,64]. Regarding soluble factors, important anti-
inflammatory molecules, such as transforming TGF-β, PGE-2, and HGF, have been
enrolled[21,23].  Through  secretion  of  TGF-β  and  other  factors,  MSC  promote  the
induction of regulatory cells, including T cells[65], macrophages[66], and B cells[67] and
thus transmit their immunosuppressive effects to different types of cells that exert
several mechanisms of immune suppression. MSC can also be induced to produce
IDO enzyme, which has an effective ability to inhibit lymphocyte proliferation by
metabolism of L-tryptophan to L-kynurenine. Thus, low levels of L-tryptophan and
high levels of L-kynurenine impose a block of lymphocyte proliferation[68].
Moreover, MSC exert their immunomodulatory function through molecules in their
cell membrane, such as ATPases and CD73 (ecto-5’-nucleotidase, Ecto5’NTase)[28,69].
ATPase converts ATP to ADP and then to AMP. CD73 further dephosphorylates AMP
to adenosine, which exhibits immunosuppressive properties[69,70]. Also, the ability of
MSC to modify the immune system response can be enhanced by treatment with
proinflammatory cytokines, TNF-α and IFN-γ in particular[19-21]. Under inflammatory
conditions,  MSC express  membrane proteins  with  an immunological  regulatory
function, such as PD-L1 and the Fas ligand, through which they direct to the target
cells and prevent their activation/function[6,22,32-34].
Interaction between MSC and immune cells: Direct cell  contact or secretion of
molecules?
Secreted bioactive molecules as well as the membrane proteins of MSC demonstrate
an ability to mediate immunosuppression. Nevertheless, there are controversies in the
literature about the interaction of MSC with immune cells[71-73]. For MSC treatments to
reach their full potential, a broader understanding of how cells exert their immunosu-
ppression must be developed. Then it will be possible to define the relevant pathways
for improving MSC treatment for specific inflammation or immune disorders.
Factors secreted by MSC have modulated the expression profile of cytokines in
macrophages,  inducing  the  polarization  of  these  cells  to  an  anti-inflammatory
phenotype (M2)[74,75]. However, González et al[63] reported a partial dependence of the
cell-cell  contact  mechanism by the induction of  secretion of  immunosuppressive
factors. In their study, different co-culture systems of adipose tissue-derived MSC and
macrophages were assessed and high levels of IL-10 were only observed in the co-
culture  system  that  promoted  cell-cell  contact.  Furthermore,  macrophages  that
phagocyte  MSC acquire  regulatory  properties[35].  In  this  sense,  bioactive  factors
and/or cell-cell interaction promote distinct types of regulatory macrophages that can
change  their  function  in  response  to  the  proinflammatory  signals  of  the  micro-
environment[76].  MSC  may  also  affect  populations  of  monocytes,  precursors  of
macrophages  and  dendritic  cells,  through  the  secretion  of  HGF  that  induces
monocytes  to  an  immunomodulatory  phenotype  (CD14+CD16 -)  with  IL-10
production[27].
However, some authors suggest that activation of T cells by MSC is independent of
cell  contact[77-79].  Several  soluble  factors  have been associated with  the  immuno-
modulatory ability of MSC to affect the activation or proliferation of T cells, such as
the  secretion of  HGF,  TGF-β,  IDO,  and PGE-2[21,23,68,71,73].  Saldanha-Araujo  et  al[80]
demonstrated an additional mechanism by which MSC suppress T cell proliferation.
This study demonstrated that, during the interaction between MSC and T cells, there
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is adenosine production by MSC, which reduce T cell proliferation by flagging the
adenosine receptor on the membrane surface. Still, other authors suggest that cell-cell
contact is essential for an intense immunosuppressive effect[78]. In fact, MSC express
integrins, intercellular adhesion molecules, and vascular cell adhesion protein on their
surface and can bind to T cells with high affinity[71,81]. Quaedackers et al[82] cultivated
MSC with peripheral blood mononuclear cells and indicated that such interaction is a
specific process, since the subpopulations of lymphocytes that interacted with MSC
were distinct from cells that remained in suspension. The T cell fraction that adhered
to  MSC was regulatory T cells  exhibiting an immunosuppressive  phenotype.  In
inflammatory environment, the expression of the molecules PD-L1 and PD-L2 on the
MSC surface enhance, restricting the function of T cells through PD-1 ligands[83]. The
high levels of these inhibitory molecules on the MSC membrane confirm that one of
the mechanisms of MSC immunosuppression is also by cell–cell contact-mediated
responses.
MSC can also immunomodulate other cell types of the innate and the adaptive
immune system,  such as  B lymphocytes,  dendritic  cells,  and natural  killer  (NK)
cells[72,84]. Luk et al[14] have demonstrated that MSC, under normal culture conditions,
promote B cell survival and induce the formation of regulatory B cells, but negligible
interference on B cell proliferation and immunoglobulin G production was observed.
However, after pre-treatment with IFN-γ, MSC appear to inhibit B cell proliferation
and reduce immunoglobulin G production, even though these primed cells lose the
ability to induce the formation of regulatory B cells. Moreover, the authors evaluated
distinct mechanisms as key factors for MSC-mediated immunomodulation. First, they
demonstrated that the effects of MSC on B cells do not depend only on soluble factors,
since no production of  regulatory B cells  or  IL-10 was induced when MSC were
cultured in a Transwell system with separated chambers. Second, they assessed that
the presence of heat-inactivated MSC (dead cells not capable of secreting factors but
phenotypically intact) was not sufficient to induce IL-10 producing B cells. These data
suggest that B cell modulation by MSC is mediated by an active metabolic process
and requires B cell and MSC contact.
Another mechanism of immunosuppression exerted by MSC has been observed in
the inhibition of the differentiation and maturation of dendritic cells derived from
CD14+ monocytes[85]. Co-culture with Transwell suggests that IL-6 and macrophage
colony stimulating factor are partially involved in the inhibition of dendritic cell
differentiation by MSC. MSC may also alter the cytokine secretion profile of dendritic
cells[86]. Co-culture with MSC demonstrates decreased secretion of TNF-α by mature
myeloid dendritic cells, while increasing IL-10 secretion by plasmacytoid dendritic
cells[87]. Moreover, MSC are sensitive to lysis by activated NK cells but are resistant to
naive NK cells[88]. Spaggiari et al[89] observed that MSC treated with IFN-γ are resistant
to lysis by NK cells. In addition, they found that some inhibitory effects of MSC on
NK cells  demand cell-cell  contact,  while  others  are  regulated by soluble  factors,
including  PGE-2  and  TGF-β1.  Therefore,  these  data  together  suggest  that  the
mechanism of immunoregulation of MSC depends on the types of cell populations,
the inflammatory conditions, and the presence or absence of cell-cell contact.
MSC THERAPY IN IBD
Autologous and allogeneic MSC have been evaluated in clinical trials in two different
modalities:  Local  injection  of  MSC to  treat  fistulizing  CD and  intravenous  (IV)
infusion of MSC to treat UC or luminal colitis[42,90-93]. Published work demonstrates that
to date 117 IBD patients with refractory disease or intolerant to standard treatment
have received one or more IV infusions of autologous or allogeneic MSC[94]. Currently,
results of clinical trials are particularly encouraging in terms of safety and efficacy;
however, due to different study designs regarding tested groups, short follow-up, and
a lack of endoscopic data and unified primary outcomes, no final conclusions can be
made.  In  fact,  MSC demonstrated  their  ability  to  repair  perianal  fistulas  in  CD
patients,  refractory  to  conventional  or  biological  therapy  in  several  controlled
trials[95,96].  Still,  MSC need to demonstrate their clear efficacy on luminal CD and
UC[97,98].
In this sense, experimental studies in animal models have contributed to a better
understanding  of  cellular,  molecular,  and  immunological  mechanisms  of  IBD
associated  with  cell  therapy.  Recent  studies  have  demonstrated  a  clinical  and
histopathological improvement of colitis after an infusion of MSC, such as decreased
inflammation and increased survival[99,100].  In addition, much has been researched
regarding the homing of exogenous MSC infused by different pathways in response
to an inflammatory insult. A comparative study between the IV and intraperitoneal
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(IP) routes in a trinitrobenzene sulfonic acid (TNBS)-induced colitis model concluded
that, in systemic administration, MSC accumulated preferentially in the lungs, with
no evidence of migration to the colon. On the other hand, MSC injected via IP were
located in the inflamed colon[101]. Another study in an experimental model of sodium
dextran sulfate (DSS)-induced colitis demonstrated that MSC migrate towards the
lung, liver, and spleen, and even a small amount to the inflamed colon after 24 h of IV
infusion. In contrast, IP and intracolonic routes showed more cell grafting in the colon
and fewer cells trapped in the pulmonary alveoli[100].  However,  a previous study
conducted by our research group also evaluated the effect of MSC administered by
different  routes,  IV and IP,  in  DSS-induced acute  colitis.  We demonstrated that
infusion of MSC by IV route decreased intestinal inflammation, modulated serum
cytokines, and induced apoptosis of T cells of the intestinal mucosa. Meanwhile, the
same effect was not found in animals treated by IP route[102].
In this way, there are controversial studies about the location and persistence of
MSC in the  body after  cell  transplantation.  The efficiency of  cellular  delivery is
dependent on the route of administration[101,102]. IV infusion, for example, has been
used as a cellular delivery route for preclinical studies[9,10,102] and for recent clinical
trials[103] due to its wide distribution and easy access. However, cell-tracking studies
have shown that most MSC are localized in the lungs and have a short-term survival
in the body after IV infusion[9-12]. The entrapment of MSC in the lungs is occasioned by
their  size[24],  which exceeds the width of  the pulmonary micro-capillaries[25,26].  In
patients, respiratory discomfort has been reported after transfusion of MSC[10]; and
high and subsequent doses of cells are usually required to observe some effect in
animal models[104]. Interestingly, in experiments of Lee et al[105], MSC retained in the
lungs improved cardiac function after myocardial infarction by releasing the anti-
inflammatory protein TSG-6[105].
After 24 h of infusion, MSC tend to disappear from the lungs, and their cellular
debris are distributed to other sites, particularly the liver, suggesting that these cells
pass their effects to the resident immune cells[106]. Then, the resident cells possibly
mediate the immunomodulatory effects induced by transplanted MSC[9]. Moreover,
immune system cells are likely to play a role in the removal of MSC. Activated NK
cells, for example, have been shown to be able to lyse autologous MSC in vitro[89]. Also,
apoptosis of infused cells may trigger an immunomodulatory response. Lu et al[35]
demonstrated that macrophages adapt a new immunoregulatory function after the
phagocytosis of dead MSC[35,107]. Based on this information, MSC probably interact
with resident cells through distinct mechanisms, either by the secretion of paracrine
factors or through a direct cell-cell interaction[13-15,108]. Intestinal organoids derived
from stem cells also provide a system to mimic ex vivo interactions between the lamina
propria  and  epithelium  intestinal  by  cell  contact–dependent/independent
mechanisms[109].
Thus,  the  application  of  MSC  in  vivo  requires,  in  addition  to  the  biological
knowledge of the cells, a deep understanding of the mechanisms involved in IBD. For
this,  the  immunological  properties  of  the MSC type,  the infusion route,  and the
inflammatory and immunological conditions of the disease should be considered.
Therefore, MSC therapy may exert its therapeutic effects mainly by secreting soluble
immunomodulating bioactive factors and/or by cell-cell contact and consequently by
interaction with immune cells, establishing a favorable environment for regeneration.
THERAPY BASED ON THE IMMUNOMODULATORY
PROPERTIES OF MSC
Infused MSC have been demonstrated to promote the intestinal repair processes in
both humans[42]  and animal  models[105,110].  Nevertheless,  the engraftment  and the
homing  mechanism  of  MSC  are  not  well  elucidated  and  depend  on  intricate
interactions between signaling pathways.  Short  survival  after  infusion and poor
biodistribution of MSC have proven to be significant technical challenges to overcome
before  this  therapy can be  used for  clinical  purposes.  An alteration  in  the  MSC
treatment that avoids these issues, but maintains the immunomodulatory properties
of MSC, would enhance this therapy. Also, though positive effects of MSC infusion
can last longer than the half-life of the cells themselves, they reduce over time. It is
thus plausible that successive MSC administrations are necessary as maintenance
therapy[94].
Bioactive factors of MSC
Recent studies have reported that the regenerative potential of MSC therapy has been,
at  least  in part,  mediated by paracrine actions[15,111,112].  Thus,  studies about MSC-
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secreted factors have demonstrated that these factors can induce tissue repair in
conditions involving tissue/organ damage[111]. Furthermore, they are referred to in the
literature as “secretome” (soluble factors), and extracellular vesicles and can be found
in the MSC culture supernatant;  thus,  the supernatant of  MSC is  a denominated
conditioned medium (CM). CM is commonly prepared by confluent MSC cultures
incubated  in  serum-free  media  for  24h  without  any  concentration,  selection,  or
purification of cell products. Therefore, the components of CM are in fact both free
soluble factors (cytokines, chemokines, and growth factors) and EVs, which may
mediate the therapeutic potential of MSC[16,113] (Figure 1).
Few studies have used the MSC-CM as a therapeutic strategy for IBD (Table 1). The
paracrine effect of MSC-CM has been observed in experimental models of colitis
induced chemically by TNBS and DSS[15,114,115]. Heidari et al[116] and Pouya et al[117] have
shown the effects of MSC-CM in DSS-induced colitis by increasing anti-inflammatory
responses associated with an increase of  regulatory T cells  percentage and IL-10
production.  Watanabe  et  al[15]  demonstrated  that  MSC-CM was  effective  for  the
inductive stage of TNBS-induced colitis and for the recovery stage of DSS-induced
colitis independent of the systemic delivery route. Similarly, Robinson et al[115] (2014)
and (2015)[118] showed that MSC and CM treatments prevented damage to the enteric
nervous system and alleviated gut dysfunction caused by TNBS-induced colitis. In
our previous study, we investigated the paracrine role of MSC in DSS-induced colitis
of colon organ culture. Our results have shown that colonic inflammation is alleviated
by MSC-CM, and this effect is independent of cell  contact[119].  Also, CM has been
evaluated in several other conditions and diseases, such as myocardial infarction[120],
bone defect[121], hepatic insufficiency[122], and spinal cord injury[123]. Liu et al[124] suggest
that MSC-CM administration has the potential to suppress proliferation of artery
smooth muscle cells in an experimental model of pulmonary hypertension. Another
study reported that  the application of  MSC-CM in diabetic  rats  prevented renal
disease, primarily by attenuating the expression of TGF-β1[125]. Therefore, it may be
observed  that  MSC-CM  contains  several  factors  that  intervene  in  different
pathophysiological manifestations, such as inflammation, proliferation, angiogenesis,
and tissue remodeling[15]. Taken together, these results indicate that MSC-secreted
factors  are  able  to  preserve  the  intestinal  barrier  in  IBD  independent  of  cell
transplantation.
MSC also have been displayed to release EVs, which can be implicated in cell-cell
interaction by carrying biologically active lipids, proteins, and nucleic acids in and on
their membrane (Table 1)[26,28]. EVs are cell-derived membranous structures released
by cells. They can be originated from multivesicular bodies (exosomes) or directly
from  the  cell  membrane  (microvesicles  -  MVs).  Both  exosomes  and  MVs  are
comprised of two regions: The membrane and the natural internal cargo. The outer
membrane, composed of lipid layer and proteins, packages bioactive molecules and
protects the internal cargo, consisting of lipids, proteins, DNA, mRNA, micro-RNA,
and other components from the parental cell. The cargo carried by EVs dictated their
function[126,127].  The MSC treatment  may be  mediated by free  soluble  factors  and
components contained in EVs, which composition is cell-origin specific[24,25,114]. Kim et
al[128] profiled MSC-derived MVs proteome and identified 730 proteins engaged in
processes associated with self-renewal and/or differentiation of MSC. Also, they
pointed out that the micro-RNAs (miRNAs) profile of MVs presents a pattern shared
with their cells of origin. Nevertheless, selected miRNAs were evident only in the
released MVs but absent in the MSC[128]. Accordingly, another study has extracted
RNA from MSC and their MVs for 365 known mature miRNAs, and they observed
that 41 miRNAs were co-expressed in MVs and cells, others were cumulated within
MVs and absent in the cells after MVs secretion, and still others were maintained
within the cells and not liberated in MVs[129].
Thus, several studies have been focused on MSC-derived EVs as a treatment for
IBD (Table 1). Wong et al[130] identified in circulating exosomes of DSS-induced colitis
mouse  56  differentially  expressed  proteins  that  are  involved  in  macrophage
activation. Wu et al[131] demonstrated the role of miR146-a in attenuating experimental
colitis since EVs derived from MSC overexpressing miR146-a significantly inhibited
TNF receptor–associated factor 6 and IL-1 receptor associated kinase 1. Yang et al[132]
demonstrated that EVs protect against TNBS-induce colitis by attenuating oxidative
stress and apoptosis. Mao et al[114] demonstrated that exosomes released from human
umbilical  cord-derived MSC homed to colon tissue of IBD mice and relieved the
severity of the DSS-induced colitis by altering the expression of inflammatory genes
and decreasing the infiltration of macrophages. Interestingly, ubiquitination may play
an important role in the anti-inflammatory effect observed in IBD animals treated
with MSC-derived exosomes. Ubiquitin is upregulated in IBD mice and promotes
activation of the nuclear factor kappa B pathway by increasing the ubiquitination and
degradation of  inhibitor  of  kappa B alpha and regulating inflammation through
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Figure 1
Figure 1  Release of bioactive factors by MSC. MSC can secrete bioactive factors including free soluble factors (cytokines, chemokines, and growth factors) and
extracellular vesicles (microvesicles and exosomes) that mediate the therapeutic potential of MSC. MSC: Mesenchymal stromal cells.
mTOR signaling. However, the expression of ubiquitin was inhibited in the colonic
mucosa and spleen after the MSC-derived exosomes treatment[133].
In this way, the secreted bioactive factors could play an essential role in repairing
damaged colon from experimental colitis to regenerative medicine. In relation to
cellular therapy, bioactive factors are easier to prepare and store. Then, it is a therapy
devoid of cells, and possible risks of rejection between donor and recipient can be
minimized.  Lastly,  pulmonary capillaries are not a barrier  for this  therapy in IV
transplantation, and CM can reach sites beyond the lung[111].
MSC membrane
There is inconclusive evidence that bioactive anti-inflammatory factors alone are
responsible for the immunomodulatory effects of transplanted MSC. The short-term
survival of MSC in the body after infusion raises the questions of whether MSC have
sufficient time to be activated by inflammatory conditions and then secreted factors[9].
Hoogduijn et al[106] found that MSC infusion initiates a mild and immediate systemic
inflammatory response, which may be the activator of posterior immunosuppression.
In this study, the inflammatory response was found in the lung and characterized by
an increased expression of pro-inflammatory monocyte and cytokines. Also, MSC
infusion provides inflammatory conditions for their activation and that at least part of
the immunomodulatory response mediated by MSC is independent of activation by
anti-inflammatory  soluble  factors.  Instead,  passive  interactions  with  host  cells
probably mediate these effects[14]. de Witte et al[134] demonstrated that infused MSC are
internalized by monocytes and induce phenotypical and functional changes in these
cells, which subsequently migrate from the lungs to other body sites and modulate
immune  cells  response.  Other  studies  also  indicated  that  MSC  induced  an
immunosuppressive phenotype on macrophages after  phagocytosis  and that  the
macrophage depletion reduced the therapeutic effect of MSC[35,135].
Based on this  analysis,  some studies  have shown that  MSC exert  their  effects
through intermediary cells by contact with the cell membrane[14,134,136,137]. MSC express
immunomodulatory molecules on their membrane, such as CD90 (Thy-1 membrane
glycoprotein) that is involved in MSC differentiation pathways, ATPases, and CD73,
which dephosphorylate ATP into AMP and AMP into adenosine, respectively[136].
Interestingly, a recent study has determined that heat-inactivated MSC preserve their
immunomodulatory  capacity  after  IV  infusion  in  a  lipopolysaccharide-induced
model, suggesting that cell-membrane-dependent interactions with immune cells are
triggering factors of the immunological regulatory effects[14]. Song et al[107] systemically
administered MSC extract obtained by cell lysis in experimental colitis, and their
results  demonstrated that  the MSC extract  polarized the macrophage functional
phenotyping from M1 to M2. This new therapeutic approach could overcome the low
homing efficiency of MSC in patients with IBD.
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Table 1  Studies using bioactive factors derived from mesenchymal stromal cells as a therapeutic strategy for inflammatory bowel
diseases
Bioactive factors MSC origin IBD model Pathway Results Ref.
CM Rat bone-marrow DSS and TNBS-induced
colitis in rats
IP, IV, and enema Effective for the
inductive phase of
TNBS-induced colitis
and for recovery phase
of DSS-induced colitis.
Watanabe et al[15], 2014
CM Human bone-marrow TNBS-induced colitis in
pigs
Enema Prevent loss of
myenteric neurons and
damage of nerve
process.
Robinson et al[115], 2014
EVs Rat bone-marrow TNBS-induced colitis in
rats
IV Inhibit NF-κBp65
pathways, modulate
anti-oxidant/oxidant
balance, and apoptosis.
Yang et al[132], 2015
Exosomes Human umbilical cord DSS-induced colitis in
mice
IV Increase IL-10 and
decrease TNF-α, IL-1β,
IL-6, iNOS, and IL-17.
Mao et al[114], 2017
Extract Human umbilical cord DSS-induced colitis in
mice
IP Inhibit inflammatory
cytokines and alter
macrophage functional
phenotype from M1 to
M2
Song et al[107], 2017
CM Mouse adipose tissue DSS-induced colitis in
mice
IP Increase Treg, IL-10, and
TGF-β, and decreased
IL-17.
Heidari et al[116], 2018
CM Mouse adipose tissue DSS-induced colitis in
mice
IP Increase Treg, IL-10, and
TGF-β, and decreased
IL-17.
Pouya et al[117], 2018
CM Human umbilical cord DSS-induced colitis in
mice
Culture medium (organ
culture)
Decrease IL-6 and
increase Ki-67.
DA Costa Gonçalves et
al[119], 2018
Exosomes Human umbilical cord DSS-induced colitis in
mice
IV Downregulated
ubiquitin inhibiting NF-
κB and mTOR
activation.
Wu et al[133], 2018
EVs Mouse bone-marrow
overexpressing miR-
146a
TNBS-induced colitis in
rats
IV Suppress the activation
of NF-kB pathway,
decrease TNF-α, IL-6,
and IL-1β.
Wu et al[131], 2019
MSC: Mesenchymal stromal cells; IBD: Inflammatory bowel diseases; DSS: Sodium dextran sulfate; CM: Conditioned medium; EVs: Extracellular vehicles;
TNBS: Trinitrobenzene sulfonic acid; IP: Intraperitoneal; IV: Intravenous; TGF: transforming growth factor; Treg: Regulator T cell; NF-κB: Nuclear factor
kappa B; IL, Interleukin; TNF-α: Tumor necrosis factor-alpha.
It is known that MSC-mediated immunosuppression is induced by inflammatory
cytokines.  Treatment  with  IFN-γ,  TNF-α,  and  IL-1β  causes  MSC  to  express
immunomodulatory  molecules  that  mediate  the  suppression  via  cell-contact
dependent mechanisms, including TLRs,  PD-L1/PD-1 pathway, and FAS-L/FAS
interaction[73,138-140] (Figure 2). Duijvestein et al[141] showed that MSC stimulated with
IFN-γ enhance their immunosuppressive capacities, resulting in diminished mucosal
damage in experimental colitis. Kang et al[142] found that IFN-γ primed MSC secrete
tryptophanyl-tRNA synthetase and alleviate the experimental colitis by inducing
apoptosis  of  immune  cells.  In  our  previous  study,  we  have  shown  that  MSC
stimulated with IFN-γ decreased lymphocyte population in colonic organ culture of
DSS-treated  mice,  but  no  effect  of  CM  treatment  was  observed.  That  could  be
explained by the fact that T cell immunosuppression has a partial dependence on the
cell-cell contact mechanism[119]. Furthermore, Fan et al[143] showed that IL-1β primed
MSC have enhanced immunosuppressive capacities and migration ability, and Cheng
et al[144] demonstrated that IL-25 primed MSC inhibited Th17 immune response and
induced regulatory T cell phenotyping in DSS-induced colitis[143,144].
In another previous study conducted by our research group, we developed a cell-
free therapy based on small particles from the membranes of MSC stimulated and
unstimulated with IFN-γ. These particles contain the membrane-bound proteins of
MSC, several of which have an immunomodulatory function and may also overcome
the low homing efficiency of MSC. We have demonstrated that membrane particles
keep immune regulatory properties of MSC and are potentially capable of passing the
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Figure 2
Figure 2  Enhanced immunosuppressive properties of MSC in cell contact-dependent mechanism. Treatment with IFN-γ and TNF-α induce MSC1 to express
immunomodulatory molecules (MSC2) that mediate the suppression via cell contact-dependent mechanisms including PD-L1/PD-1 pathway and FAS-L/FAS
interaction. To improve MSC homing, new therapeutic approaches are being developed: Heat-inactivated cells and lysed cells (extract or cell membrane). MSC-based
therapy may exert its therapeutic effects mainly by cell-cell contact and consequently by interaction with immune cells, establishing a favorable environment for the
regeneration of intestinal tissue. MSC: Mesenchymal stromal cells; IFN: Interferon; TNF: Tumor necrosis factor; PD-L1: Programmed death ligand 1; IDO: Indoleamine
2,3 dioxygenase.
lung barrier and exerting their effects at sites beyond the lungs[136]. Most importantly,
we also found that the immunomodulation induced by membrane particles stimu-
lated and unstimulated with IFN- γ is different. According to this information, the
surface  phenotype  of  MSC  (protein  molecules  present  on  their  membrane)  is
determinants for the therapeutic effect of MSC in patients with IBD.
CONCLUSION
Taken together, these findings highlight that bioactive factors, cell surface proteins,
and  metabolic  pathways  derived  from  MSC  offer  unique  opportunities  for  the
development of promising cell-free therapies for IBD that associate the potential of
MSC with the reduction of the practical complexities arising from the use of living
cells.  Recent  experimental  studies  have suggested that  not  only the  secretion of
bioactive factors but also the surface proteins of MSC have great therapeutic potential
that can overcome the deficiencies of current therapy for IBD and could open new
frontiers in gastrointestinal medicine.
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